Nature Communications (Dec 2017)
The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury
- Lucía Barbier-Torres,
- Paula Iruzubieta,
- David Fernández-Ramos,
- Teresa C. Delgado,
- Daniel Taibo,
- Virginia Guitiérrez-de-Juan,
- Marta Varela-Rey,
- Mikel Azkargorta,
- Nicolas Navasa,
- Pablo Fernández-Tussy,
- Imanol Zubiete-Franco,
- Jorge Simon,
- Fernando Lopitz-Otsoa,
- Sofia Lachiondo-Ortega,
- Javier Crespo,
- Steven Masson,
- Misti Vanette McCain,
- Erica Villa,
- Helen Reeves,
- Felix Elortza,
- Maria Isabel Lucena,
- Maria Isabel Hernández-Alvarez,
- Antonio Zorzano,
- Raúl J. Andrade,
- Shelly C. Lu,
- José M. Mato,
- Juan Anguita,
- Mercedes Rincón,
- María Luz Martínez-Chantar
Affiliations
- Lucía Barbier-Torres
- Liver Disease Laboratory and Liver Metabolism Laboratory, CIC bioGUNE, CIBERehd, Bizkaia Science and Technology Park
- Paula Iruzubieta
- Liver Disease Laboratory and Liver Metabolism Laboratory, CIC bioGUNE, CIBERehd, Bizkaia Science and Technology Park
- David Fernández-Ramos
- Liver Disease Laboratory and Liver Metabolism Laboratory, CIC bioGUNE, CIBERehd, Bizkaia Science and Technology Park
- Teresa C. Delgado
- Liver Disease Laboratory and Liver Metabolism Laboratory, CIC bioGUNE, CIBERehd, Bizkaia Science and Technology Park
- Daniel Taibo
- Liver Disease Laboratory and Liver Metabolism Laboratory, CIC bioGUNE, CIBERehd, Bizkaia Science and Technology Park
- Virginia Guitiérrez-de-Juan
- Liver Disease Laboratory and Liver Metabolism Laboratory, CIC bioGUNE, CIBERehd, Bizkaia Science and Technology Park
- Marta Varela-Rey
- Liver Disease Laboratory and Liver Metabolism Laboratory, CIC bioGUNE, CIBERehd, Bizkaia Science and Technology Park
- Mikel Azkargorta
- Proteomics Platform, CIC bioGUNE, CIBERehd, ProteoRed-ISCIII, Bizkaia Science and Technology Park
- Nicolas Navasa
- Macrophage and Tick Vaccine Laboratory, CIC bioGUNE, Bizkaia Science and Technology Park
- Pablo Fernández-Tussy
- Liver Disease Laboratory and Liver Metabolism Laboratory, CIC bioGUNE, CIBERehd, Bizkaia Science and Technology Park
- Imanol Zubiete-Franco
- Liver Disease Laboratory and Liver Metabolism Laboratory, CIC bioGUNE, CIBERehd, Bizkaia Science and Technology Park
- Jorge Simon
- Liver Disease Laboratory and Liver Metabolism Laboratory, CIC bioGUNE, CIBERehd, Bizkaia Science and Technology Park
- Fernando Lopitz-Otsoa
- Liver Disease Laboratory and Liver Metabolism Laboratory, CIC bioGUNE, CIBERehd, Bizkaia Science and Technology Park
- Sofia Lachiondo-Ortega
- Liver Disease Laboratory and Liver Metabolism Laboratory, CIC bioGUNE, CIBERehd, Bizkaia Science and Technology Park
- Javier Crespo
- Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd). Infection, Immunity and Digestive Pathology Group, Research Institute Marqués de Valdecilla (IDIVAL)
- Steven Masson
- The Liver Unit, Newcastle-upon-Tyne Hospitals NHS Foundation Trust
- Misti Vanette McCain
- Northern Institute of Cancer Research, The Medical School, Newcastle University
- Erica Villa
- Gastroenterology Unit, Department of Internal Medicine, University of Modena and Reggio Emilia
- Helen Reeves
- The Liver Unit, Newcastle-upon-Tyne Hospitals NHS Foundation Trust
- Felix Elortza
- Proteomics Platform, CIC bioGUNE, CIBERehd, ProteoRed-ISCIII, Bizkaia Science and Technology Park
- Maria Isabel Lucena
- University Hospital Virgen de la Victoria
- Maria Isabel Hernández-Alvarez
- Institute for Research in Biomedicine (IRB Barcelona)
- Antonio Zorzano
- Institute for Research in Biomedicine (IRB Barcelona)
- Raúl J. Andrade
- University Hospital Virgen de la Victoria
- Shelly C. Lu
- Division of Gastroenterology, Cedars-Sinai Medical Center
- José M. Mato
- Liver Disease Laboratory and Liver Metabolism Laboratory, CIC bioGUNE, CIBERehd, Bizkaia Science and Technology Park
- Juan Anguita
- Macrophage and Tick Vaccine Laboratory, CIC bioGUNE, Bizkaia Science and Technology Park
- Mercedes Rincón
- Department of Medicine, University of Vermont College of Medicine
- María Luz Martínez-Chantar
- Liver Disease Laboratory and Liver Metabolism Laboratory, CIC bioGUNE, CIBERehd, Bizkaia Science and Technology Park
- DOI
- https://doi.org/10.1038/s41467-017-01970-x
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 11
Abstract
Acetaminophen-induced liver injury is one of the most common causes of liver failure and has to be treated within hours of the overdose. Here Barbier-Torres et al. show that targeting MCJ, a mitochondrial negative regulator, even 24 h after the overdose protects liver from acetaminophen-induced damage.
